3C-E

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-10-19issueIssued notice
4. 2026-09-07srcChemistry and Structure-Activity Relationships of Psychedelics.
5. 2026-09-07srcFlashbacks, Hallucinogen Persisting Perception Disorder (HPPD), and Reactivations Following the Use of Classic Psychedelics: Classification and Therapeutic Management
6. 2026-09-07srcOpioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects
7. 2026-09-07srcDesigner drugs: mechanism of action and adverse effects
8. 2026-09-07srcHallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines.
9. 2026-09-07src5-hydroxytryptamine- and dopamine-releasing effects of ring-substituted amphetamines on rat brain: a comparative study using in vivo microdialysis
10. 2026-09-07srcRole of the 5-HT2A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice
11. 2026-09-07srcCorrelation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
12. 2026-09-07srcMescaline: The forgotten psychedelic
13. 2026-09-07src2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.
14. 2026-09-07srcInvestigation of the 2,5-Dimethoxy Motif in Phenethylamine Serotonin 2A Receptor Agonists
15. 2026-09-07srcTolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
16. 2026-09-07srcComparison of the behavioral effects of mescaline analogs using the head twitch response in mice
17. 2026-09-07srcPeakAL: Protons I Have Known and Loved — NMR spectra of psychedelic phenylethanamines including TMA-2
18. 2026-09-07srcReceptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines.
19. 2026-09-07srcDifferential phospholipase C activation by phenylalkylamine serotonin 5-HT2A receptor agonists
20. 2026-09-07srcLysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain
21. 2026-09-07srcEffect of a chiral 4-alkyl substituent in hallucinogenic amphetamines.
22. 2026-09-07srcDihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives
23. 2026-09-07src3C-E chemical and pharmacological data
24. 2026-09-07srcPiHKAL Entry #25: 3C-E (3,5-Dimethoxy-4-Ethoxyamphetamine)
25. 2026-09-07src3C-E legal status and scheduling
26. 2026-09-04issueIssued emergency
27. 2026-09-04issueIssued info_card
28. 2026-09-04issueIssued notice
29. 2026-06-04proposal37 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
30. 2026-06-04publicationPublication — backfill
31. 2026-05-11revisionRevision 1
32. 2026-05-11absenceSearched ClinicalTrials.gov for "3C-E mescaline analog phenethylamine psychedelic" — no results
33. 2026-05-11absenceSearched PubMed for "3C-E 1-(4-ethoxy-3,5-dimethoxyphenyl)propan-2-amine psychedelic phenethylamine" — no results
34. 2026-05-11genGeneration — pipeline-v5 · with 4 morepipeline-v5
35. 2026-05-11rungeneration run

The same entries, as forms: six forms.